The FDA Office of Generic Drugs reported a rise in generic drug approvals, as se...
The positive opinion is based on findings from the Phase III COMMANDS trial whic...
Sanofi and Regeneron’s Dupixent has received priority review by the US FDA, with...
Following major successes in the RSV landscape over the last few years, experts ...
The widespread use of new weight loss drugs in the U.S. could boost gross domest...
In an interview, Alnylam’s CEO defended changes to its all-important cardiovascu...
It was a controversial choice for Annovis Bio to change the endpoint of a Phase ...
Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire...
People are choosing home birth for vaginal delivery after cesarian and other hig...
STAT+ subscribers tried to stump Pharmalot, aka Ed Silverman. Here’s what they c...
Abridge, a Pittsburgh AI startup emerging as a challenger to Microsoft’s clinica...
The FDA said it is not planning to take a tougher stance against wayward clinica...
This week on "The Readout LOUD" podcast: What do CEOs owe the world? Did Humira ...
Embryo loss is integral to IVF. Alabama’s ruling equating embryos with children ...
San Diego-based Neurocrine Biosciences joins PhRMA as trade group rebuilds its m...
A bizarre court case led to an unthinkable ruling in Alabama that effectively li...
